Pallas Health Tirzepatide Review: Four-Week Pricing, Renewal and Refund Limits (2026)

Pallas now publishes $179 for the first four weeks of compounded tirzepatide, then $299 every four weeks. That replaces the twelve-week-only structure described in our earlier review. The current shorter renewal period is a meaningful change for someone deciding how much treatment to buy at once. Our link to Pallas is direct; we do not currently earn a commission from this provider.

Program information checked October 6, 2026. Prices and policies below describe the public pages linked in the sources; individual eligibility and checkout terms can differ.

A four-week bill is not a calendar-month bill

At the standing rate, thirteen four-week periods cover 52 weeks and cost $3,887. With one $179 introductory period followed by twelve $299 periods, the same 52-week supply costs $3,767, assuming unchanged pricing and uninterrupted treatment. These are our calculations, not an advertised annual quote. They also do not describe the exact date a card is charged.

Pallas separately advertises an annual option at $239 per month on average. We have not treated that average as a monthly payment or assumed its upfront total. Compare the written annual invoice with the four-week option before choosing. A lower average matters only if you are comfortable with the amount committed.

What is included, and when a charge becomes final

The public page includes clinician visits, messaging and shipping, with no separate membership and no dose surcharge for the compounded plan. It says the charge occurs when a clinician prescribes. Cancellation or pausing prevents future billing; the prescription charge is final once issued. The page applies that policy to purchases from July 14, 2026, and directs older purchases to their original terms.¹

That distinction makes the moment of prescribing important. Submit a cancellation before the next prescribing and billing event if you do not intend to continue, and keep the confirmation. Stopping future renewals does not imply a refund for the period already prescribed.

Clinical access and remaining uncertainty

Pallas describes US-licensed clinicians and advertises national access, but an individual prescription still depends on eligibility and local availability. We did not verify a named dispensing pharmacy for this review. Obtain the pharmacy identity and your state-specific appointment requirements before payment. A public price is useful transparency; it does not independently establish the quality of an individual prescription.

Alternatives worth comparing

Compare Found for another program using four-week billing, with separate insured and cash-pay terms. Compare Lavender Sky Health if choosing among named pharmacy plans matters more than a single bundled rate.

Medication evidence and safety

This is a review of published program information, not a firsthand treatment report. Compounded tirzepatide is not an FDA-approved product and should not be treated as interchangeable with branded Zepbound. For clinical questions, use our tirzepatide evidence guide and side-effect guide, and discuss your own treatment with a licensed clinician.